English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88657/118248 (75%)
Visitors : 23504411      Online Users : 234
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/123315


    Title: 論我國專利期間的調整與延長、資料專屬權與專利連結制度之發展現況--藥品智慧財產權保護相關修正草案評析
    Development of Patent Term Adjustment and Extension, Data Exclusivity and Patent Linkage in Taiwan-Analysis on the Latest Draft Amendment Related to Pharmaceutical Intel-lectual Property Protection
    Authors: 江浣翠
    Contributors: 政大智慧財產評論 
    Keywords: 跨太平洋夥伴協定;專利權期間調整;專利權期間延長;資料專屬權;專利連結
    Trans-Pacific Partnership Agreement (TPP);Patent Term Adjustment;Patent Term Extention;Data Exclusivity;Patent Linkage
    Date: 2017-03
    Issue Date: 2019-05-10 10:31:22 (UTC+8)
    Abstract: 跨太平洋夥伴協定(The Trans-Pacific Partnership Agreement,以下簡稱TPP協定)歷經數年談判,12個締約國於2015年10月6日正式達成協議,並於2016年2月4日簽署。我國政府原本擬加入TPP協定,以參與多邊貿易協定爭取我國較有利的貿易地位。惟2016年11月8日,唐納川普當選美國總統,TPP協定的未來發展充滿變數。然TPP協定中智慧財產權章,特別是與藥品相關部份,係對美國最有利的部分之一;而美國提案立場與各國談判結果,對我國未來與美經貿談判亦有重要參考價值,我國目前針對藥品智財相關之專利法與藥事法修正草案,政府實有繼續推動之誘因。是此,本文將介紹TPP協定智慧財產權專章中,專利權期間的調整與延長、資料專屬權與專利連結部分之美國提案、最終談判結果與台灣政府目前相關的修法計畫,最後並就我國專利法制、藥政管理與製藥產業可能發生之衝擊提出評論。
    After negotiating for several years, 12 members reached the Trans-Pacific Partnership Agreement (TPP Agreement) on October 6th 2015 and singed on February 4th 2016. Taiwan’s government made the policy to join the TPP Agreement. Unfortunately, Donald J. Trump’s victory of the presidency creates uncertainty of TPP’s future. However, The Intellectual Property Chapter in the TPP, especially the part related to pharmaceuticals is beneficial to the U.S.; therefore, the U.S.’s proposal and final version of the TPP are still an important reference to us for our future trade negotiation with the U.S.. Because of this fact, Taiwan’s government still has incentive to promote the proposal of revising Patent Act and Pharmaceutical Affair Act in Taiwan. This article introduces the U.S’s proposal and the provisions of TPP Agreement about patent term adjustment and extention, data exclusivity and patent linkage of pharmaceutical patents. In addition, it explores Taiwan’s related proposal of revising Patent Act and Pharmaceutical Affair Act. Eventually, this article discusses the possible impact to Taiwan’s pharmaceutical industry, patent law and patent litigation.
    Relation: 政大智慧財產評論, 14(2), 79-120
    Data Type: article
    Appears in Collections:[智慧財產評論] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML37View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback